Sign Out
Vildagliptin inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Vildaglit is indicated as an adjunct to diet and exercise to improve glycaemic control in patients with type 2 diabetes mellitus: As monotherapy; In dual combination with Metformin, a Sulphonylurea, a Thiazolidinedione, or Insulin when diet, exercise and a single antidiabetic agent do not result in adequate glycaemic control.
